Cystoid macular edema associated with retinitis pigmentosa: clinic, diagnostic, treatment approaches

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Retinitis pigmentosa (RP) is a genetically determined degenerative retinal disease characterized by primary progressive degeneration of rod and secondary degeneration of cone photoreceptors. Despite the fact that the central retinal zone remains relatively intact for a long time, the most common complication of RP is macular edema (ME). The causes of ME in patients with RP have not been finally established, and treatment approaches are controversial. This article presents the modern data on the pathogenesis, clinical aspects, diagnostic, and treatment methods of ME associated with RP.

Full Text

Restricted Access

About the authors

Ekaterina V. Denisova

Federal State Budgetary Institution «Helmholtz National Medical Research Center of Eye Diseases» of the Ministry of Health of the Russian Federation

Author for correspondence.
Email: deale_2006@inbox.ru
ORCID iD: 0000-0003-3735-6249

MD, PhD

Russian Federation, 105062 Moscow, Russia

Mariia A. Khrabrova

Federal State Budgetary Institution «Helmholtz National Medical Research Center of Eye Diseases» of the Ministry of Health of the Russian Federation

Email: lovin68@yandex.ru
ORCID iD: 0000-0001-9422-4264

MD

Russian Federation, Moscow, 105062, Russian Federation

References

  1. Artunay O, Yuzbasioglu E, Rasier R, et al. Intravitreal ranibizumab in the treatment of cystoid macular edema associated with retinitis pigmentosa. J Ocul Pharmacol Ther. 2009;25(6):545-550. doi: 10.1089/jop.2009.0089
  2. Barge S, Rothwell R, Sepúlveda P, Agrelos L. Intravitreal and subtenon depot triamcinolone as treatment of retinitis pigmentosa associated cystoid macular edema. Case Rep Ophthalmol Med. 2013;2013:591681. doi: 10.1155/2013/591681
  3. Adackapara CA, Sunness JS, Dibernardo CW, et al. Prevalence of cystoid macular edema and stability in oct retinal thickness in eyes with retinitis pigmentosa during a 48-week lutein trial. Retina. 2008;28(1):103-110. doi: 10.1097/IAE.0b013e31809862aa
  4. Hajali M, Fishman GA. The prevalence of cystoid macular oedema on optical coherence tomography in retinitis pigmentosa patients without cystic changes on fundus examination. Eye (Lond). 2009;23(4):915-919. doi: 10.1038/eye.2008.110
  5. Hirakawa H, Iijima H, Gohdo T, Tsukahara S. Optical coherence tomography of cystoid macular edema associated with retinitis pigmentosa. Am J Ophthalmol. 1999;128(2):185-191. doi: 10.1016/S0002-9394(99)00100-2
  6. Kim YJ, Joe SG, Lee DH, et al. Correlations between spectral-domain OCT measurements and visual acuity in cystoid macular edema associated with retinitis pigmentosa. Invest Ophthalmol Vis Sci. 2013;54(2):1303–1309. doi: 10.1167/iovs.12-10149
  7. Küchle M, Nguyen NX, Martus P, et al. Aqueous flare in retinitis pigmentosa. Graefes Arch Clin Exp Ophthalmol. 1998;236(6):426-433. doi: 10.1007/s004170050101
  8. Sandberg MA, Brockhurst RJ, Gaudio AR, Berson EL. Visual acuity is related to parafoveal retinal thickness in patients with retinitis pigmentosa and macular cysts. Invest Ophthalmol Vis Sci. 2008;49(10):4568-4572. doi: 10.1167/iovs.08-1992
  9. Testa F, Rossi S, Colucci R, et al. Macular abnormalities in Italian patients with retinitis pigmentosa. Br J Ophthalmol. 2014;98(7):946-950. doi: 10.1136/bjophthalmol-2013-304082
  10. Vinores SA, Kuchle M, Derevjanik NL, et al. Blood-retinal barrier breakdown in retinitis pigmentosa: light and electron microscopic immunolocalization. Histol Histopathol. 1995;1(10):913-923.
  11. Reichenbach A, Wurm A, Pannicke T, et al. Muller cells as players in retinal degeneration and edema. Graefes Arch Clin Exp Ophthalmol. 2007;245(5):627-636. doi: 10.1007/s00417-006-0516-y
  12. Makiyama Y, Oishi A, Otani A, et al. Prevalence and spatial distribution of cystoid spaces in retinitis pigmentosa: investigation with spectral domain optical coherence tomography. Retina. 2014;34(5):981-988. doi: 10.1097/IAE.0000000000000010
  13. Yeo JH, Kim YJ, Yoon YH. Optical coherence tomography angiography in patients with retinitis pigmentosa–associated cystoid macular edema. Retina. 2020;40(12):2385–2395. doi: 10.1097/IAE.0000000000002756
  14. Chung H, Hwang J, Kim J. Optical coherence tomography in the diagnosis and monitoring of cystoid macular edema in patients with retinitis. Retina. 2006;26(8):922-927. doi: 10.1097/01.iae.0000250008.83779.23
  15. Newsome DA. Retinal fluorescein leakage in retinitis pigmentosa. Am J Ophthalmol. 1986;101(3):354-360. doi: 10.1016/0002-9394(86)90831-7
  16. Heckenlively JR, Jordan BL, Aptsiauri N. Association of antiretinal antibodies and cystoid macular edema in patients with retinitis pigmentosa. Am J Ophthalmol. 1999;127(5):565-573. doi: 10.1016/s0002-9394(98)00446-2
  17. Takezawa M, Tetsuka S, Kakehashi A. Tangential vitreous traction: a possible mechanism of development of cystoid macular edema in retinitis pigmentosa. Clin Ophthalmol. 2011;5(1):245-248. doi: 10.2147/OPTH.S16891
  18. Kim C, Chung H, Gon YuH. Association of p.P347L in the rhodopsin gene with early-onset cystoid macular edema in patients with retinitis pigmentosa. Ophthalmic Genet. 2012;33(2):96-99. doi: 10.3109/13816810.2011.642453
  19. Oishi A, Otani A, Sasahara M, et al. Photoreceptor integrity and visual acuity in cystoid macular oedema associated with retinitis pigmentosa. Eye (Lond). 2009;23(6):1411-1146. doi: 10.1038/eye.2008.266
  20. Sandberg MA, Brockhurst RJ, Gaudio AR, Berson EL. The association between visual acuity and central retinal thickness in retinitis pigmentosa. Invest Ophthalmol Vis Sci. 2005;46(9):3349-3354. doi: 10.1167/iovs.04-1383
  21. Apushkin MA, Fishman GA, Janowicz MJ. Monitoring cystoid macular edema by optical coherence tomography in patients with retinitis pigmentosa. Ophthalmology. 2004;111(10):1899-1904. doi: 10.1016/j.ophtha.2004.04.019
  22. Apushkin MA, Fishman GA, Grover S, Janowicz MJ. Rebound of cystoid macular edema with continued use of acetazolamide in patients with retinitis pigmentosa. Retina. 2007;27(8):1112-1118. doi: 10.1097/IAE.0b013e31805f6b79
  23. Stanga PE, Downes SM, Ahuja RM, et al. Comparison of optical coherence tomography and fluorescein angiography in assessing macular edema in retinal dystrophies: preliminary results. Int Ophthalmol. 2001;23(4-6):321-325. doi: 10.1023/a:1014438213665
  24. Mosin IM, Slavinskaya NV, Korkh NL, Neudakhina EA. Kistoznyi makulyarnyi otek pri pigmentnom retinite (monitoring estestvennogo techeniya u detei s ispol’zovaniem opticheskoi kogerentnoi tomografii, elektrofiziologicheskikhi psikhofizicheskikh issledovanii). Oftal’mokhirurgiya. 2007;(2):57-62. (In Russ).
  25. Zolnikova V, Levina DV, Okhotsimskaya TD, et al. Electroretinography and OCT angiography of the retina and optic nerve in retinitis pigmentosa. Russian Ophthalmological Journal. 2017;10(3):22-28. (In Russ). doi: 10.21516/2072-0076-2017-10-3-22-28
  26. Minnella AM, Falsini B, Bamonte G, et al. Optical coherence tomography and focal electroretinogram evaluation of cystoid macular edema secondary to retinitis pigmentosa treated with intravitreal triamcinolone: case report. Eur J Ophthalmol. 2006;16(6):883-886. doi: 10.1177/112067210601600620
  27. Karasu B. Short-term outcomes of subtenon triamcinolone acetonide injections in patients with retinitis pigmentosa-associated cystoid macular edema unresponsive to carbonic anhydrase inhibitors. Int Ophthalmol. 2020;40(3):677-687. doi: 10.1007/s10792-019-01228-z
  28. Strong S, Liew G, Michaelides M. Retinitis pigmentosa-associated cystoid macular oedema: pathogenesis and avenues of intervention. Br J Ophthalmol. 2017;101(1):31-37. doi: 10.1136/bjophthalmol-2016-309376
  29. Fishman GA, Apushkin MA. Continued use of dorzolamide for the treatment of cystoid macular oedema in patients with retinitis pigmentosa. Br J Ophthalmol. 2007;91(6):743–745. doi: 10.1136/bjo.2006.107466
  30. Genead MA, Fishman GA. Efficacy of sustained topical dorzolamide therapy for cystic macular lesions in patients with retinitis pigmentosa and usher syndrome. Arch Ophthalmol. 2010;128(9):1146-1150. doi: 10.1001/archophthalmol.2010.172
  31. Grover S, Apushkin MA, Fishman GA. Topical dorzolamide for the treatment of cystoid macular edema in patients with retinitis pigmentosa. Am J Ophthalmol. 2006;141(5):850-858. doi: 10.1016/j.ajo.2005.12.030
  32. Ikeda Y, Hisatomi T, Yoshida N, et al. The clinical efficacy of a topical dorzolamide in the management of cystoid macular edema in patients with retinitis pigmentosa. Graefes Arch Clin Exp Ophthalmol. 2012;250(6):809-814. doi: 10.1007/s00417-011-1904-5
  33. Liew G, Moore AT, Webster AR, et al. Efficacy and prognostic factors of response to carbonic anhydrase inhibitors in management of cystoid macular edema in retinitis pigmentosa. Invest Ophthalmol Vis Sci. 2015;56(3):1531-156. doi: 10.1167/iovs.14-15995
  34. Fishman GA, Gilbert LD, Anderson RJ, et al. Effect of methazolamide on chronic macular edema in patients with retinitis pigmentosa. Ophthalmology. 1994;101(4):687-693. doi: 10.1016/s0161-6420(94)31277-2
  35. Fishman GA, Gilbert LD, Fiscella RG, et al. Acetazolamide for treatment of chronic macular edema in retinitis pigmentosa. Arch Ophthalmol. 1989;107(10):1445-1452. doi: 10.1001/archopht.1989.01070020519031
  36. Thobani A, Fishman GA. The use of carbonic anhydrase inhibitors in the retreatment of cystic macular lesions in retinitis pigmentosa and X-linked retinoschisis. Retina. 2011;31(2):312-315. doi: 10.1097/IAE.0b013e3181e587f9
  37. Scruggs BA, Chen CV, Pfeifer W, et al. Efficacy of topical brinzolamide in children with retinal dystrophies. Ophthalmic Genet. 2019;40(4):350–358. doi: 10.1080/13816810.2019.1660381
  38. Kitahata S, Hirami Y, Takagi S, et al. Efficacy of additional topical betamethasone in persistent cystoid macular oedema after carbonic anhydrase inhibitor treatments in retinitis pigmentosa. BMJ Open Ophthalmol. 2018;3(1):e000107. doi: 10.1136/bmjophth-2017-000107
  39. Schaal Y, Hondur AM, Tezel TH. Subtenon triamcinolone for cystoid macular edema due to retinitis pigmentosa unresponsive to oral acetazolamide. Can J Ophthalmol. 2016;51(4):e113-115. doi: 10.1016/j.jcjo.2015.12.021
  40. Ozdemir H, Karacorlu M, Karacorlu S. Intravitreal triamcinolone acetonide for treatment of cystoid macular oedema in patients with retinitis pigmentosa. Acta Ophthalmol Scand. 2005;83(2):248-251. doi: 10.1111/j.1600-0420.2005.00395.x
  41. Saraiva VS, Sallum JM, Farah ME. Treatment of cystoid macular edema related to retinitis pigmentosa with intravitreal triamcinolone acetonide. Ophthalmic Surg Lasers Imaging. 2003;34(5):398–400. doi: 10.3928/1542-8877-20030901-11
  42. Scorolli L, Morara M, Meduri A, et al. Treatment of cystoid macular edema in retinitis pigmentosa with intravitreal triamcinolone. Arch Ophthalmol. 2007;125(6):759-764. doi: 10.1001/archopht.125.6.759
  43. Mansour AM, Sheheitli H, Kucukerdonmez C, et al. Intravitreal dexamethasone implant in retinitis pigmentosa–related cystoid macular edema. Retina. 2018;38(2):413-423. doi: 10.1097/IAE.0000000000001542
  44. Donmez O, Saatci AO. Intravitreal pharmacotherapy in the treatment of retinitis pigmentosa-related cystoid macular oedema. European ophthalmic review. 2017;11(1):55-80. doi: 10.17925/EOR.2017.11.01.55
  45. Srour M, Querques G, Leveziel N, et al. Intravitreal dexamethasone implant (Ozurdex) for macular edema secondary to retinitis pigmentosa. Graefes Arch Clin Exp Ophthalmol. 2012;251(6):1501-1506. doi: 10.1007/s00417-012-2249-4
  46. Sudhalkar A, Kodjikian L, Borse N. Intravitreal dexamethasone implant for recalcitrant cystoid macular edema secondary to retinitis pigmentosa: a pilot study. Graefes Arch Clin Exp Ophthalmol. 2017;255(7):1369-1374. doi: 10.1007/s00417-017-3660-7
  47. Park UC, Park JH, Ma DJ, et al. A randomized paired-eye trial of intravitreal dexamethasone implant for cystoid macular edema in retinitis pigmentosa. Retina. 2019;40(7):1359-1366. doi: 10.1097/IAE.0000000000002589
  48. Chang YS, Wu CL, Tseng SH, et al. Cytotoxicity of triamcinolone on cultured human retinal pigment epithelial cells: comparison with dexamethasone and hydrocortisone. Jpn J Ophthalmol. 2004;48(3):236-242. doi: 10.1007/s10384-003-0053-8
  49. Giusti C, Forte R, Vingolo EM. Deflazacort treatment of cystoid macular edema in patients affected by Retinitis Pigmentosa: a pilot study. Eur Rev Med Pharmacol Sci. 2002;6(1):1-8.
  50. Querques G, Prascina F, Iaculli C, Noci ND. Intravitreal pegaptanib sodium (Macugen) for refractory cystoid macular edema in pericentral retinitis pigmentosa. Int Ophthalmol. 2007;29(2):103-107. doi: 10.1007/s10792-007-9175-1
  51. Yuzbasioglu E, Artunay O, Rasier R, et al. Intravitreal bevacizumab (Avastin) injection in retinitis pigmentosa. Curr Eye Res. 2009;34(3):231-237. doi: 10.1080/02713680802710692
  52. Melo GB, Farah ME, Aggio FB. Intravitreal injection of bevacizumab for cystoid macular edema in retinitis pigmentosa. Acta Ophthalmol Scand. 2007;85(4):461-443. doi: 10.1111/j.1600-0420.2006.00872.x
  53. Moustafa GA, Moschos MM. Intravitreal aflibercept (Eylea) injection for cystoid macular edema secondary to retinitis pigmentosa – a first case report and short review of the literature. BMC Ophthalmol. 2015;15(44):1-6. doi: 10.1186/s12886-015-0033-z
  54. Strong S, Peto T, Bunce C, et al. Prospective exploratory study to assess the safety and efficacy of aflibercept in cystoid macular oedema associated with retinitis pigmentosa. Br J Ophthalmol. 2020;104(1):1203-1208. doi: 10.1136/bjophthalmol-2019-315152
  55. Garcia-Arumi J, Martinez V, Sararols L, Corcostegui B. Vitreoretinal surgery for cystoid macular edema associated with retinitis pigmentosa. Ophthalmology. 2003;110(6):1164-1169. doi: 10.1016/S0161-6420(03)00259-8
  56. Hagiwara A, Yamamoto S, Ogata K, et al. Macular abnormalities in patients with retinitis pigmentosa: prevalence on OCT examination and outcomes of vitreoretinal surgery. Acta Ophthalmol. 2011;89(2):122-125. doi: 10.1111/j.1755-3768.2010.01866.x

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2020 Eco-Vector


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 86503 от 11.12.2023 г. 
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ЭЛ № ФС 77 - 80630 от 15.03.2021 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies